A detailed history of Daiwa Securities Group Inc. transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 31,709 shares of BBIO stock, worth $839,971. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,709
Previous 35,709 11.2%
Holding current value
$839,971
Previous $904,000 10.73%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$23.91 - $31.3 $95,640 - $125,200
-4,000 Reduced 11.2%
31,709 $807,000
Q2 2024

Aug 07, 2024

BUY
$23.0 - $31.04 $806,357 - $1.09 Million
35,059 Added 5393.69%
35,709 $904,000
Q1 2024

May 02, 2024

SELL
$27.35 - $40.45 $1,668 - $2,467
-61 Reduced 8.58%
650 $20,000
Q4 2023

Jan 31, 2024

BUY
$24.02 - $43.89 $3,867 - $7,066
161 Added 29.27%
711 $29,000
Q2 2023

Jul 31, 2023

SELL
$13.29 - $18.01 $102,957 - $139,523
-7,747 Reduced 93.37%
550 $9,000
Q1 2023

May 02, 2023

BUY
$7.17 - $18.55 $10,912 - $28,233
1,522 Added 22.46%
8,297 $138,000
Q4 2022

Feb 06, 2023

SELL
$6.74 - $11.52 $13,702 - $23,420
-2,033 Reduced 23.08%
6,775 $52,000
Q3 2022

Nov 02, 2022

BUY
$7.94 - $12.36 $65,568 - $102,068
8,258 Added 1501.45%
8,808 $88,000
Q2 2022

Aug 09, 2022

BUY
$5.21 - $12.14 $630 - $1,468
121 Added 28.21%
550 $5,000
Q4 2021

Feb 03, 2022

SELL
$11.38 - $53.41 $955 - $4,486
-84 Reduced 16.37%
429 $7,000
Q3 2021

Nov 05, 2021

BUY
$46.87 - $64.24 $10,217 - $14,004
218 Added 73.9%
513 $24,000
Q1 2021

May 03, 2021

BUY
$55.47 - $72.35 $3,550 - $4,630
64 Added 27.71%
295 $18,000
Q4 2020

Feb 04, 2021

SELL
$38.38 - $71.11 $17,885 - $33,137
-466 Reduced 66.86%
231 $16,000
Q4 2019

Jan 31, 2020

BUY
$17.96 - $46.63 $12,518 - $32,501
697 New
697 $24,000

Others Institutions Holding BBIO

About BridgeBio Pharma, Inc.


  • Ticker BBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 148,246,000
  • Market Cap $3.93B
  • Description
  • BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...
More about BBIO
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.